mRNA vaccine plus immunotherapy after pancreatic cancer surgery
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a personalized mRNA vaccine combined with an immunotherapy drug (PD-1 inhibitor) to prevent pancreatic cancer from returning after surgery. It is for patients whose tumors have specific genetic features and who cannot have standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had surgery to remove pancreatic cancer 1 to 3 months ago.
- You have had genetic testing of your tumor to find markers that make the vaccine more effective.
- You are not able to or you cannot have chemotherapy right now.
- You are 18 years or older.
- You do not have a history of lung disease like fibrosis or interstitial lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized vaccine made from your own tumor's genetic information. The vaccine is given after surgery to try to train your immune system to fight any remaining cancer cells and reduce the chance of the cancer coming back.
This study tests a personalized vaccine made from your own tumor, combined with a drug that helps your immune system fight cancer cells. The goal is to see if this approach can help prevent your pancreatic cancer from coming back after surgery.
This study tests a personalized vaccine made from your tumor's unique markers. It aims to help your immune system attack pancreatic cancer that has spread or returned.
This study tests messenger RNA (mRNA) vaccines, given alone or with other treatments, after surgery for pancreatic cancer. The goal is to see if the vaccines can help prevent the cancer from coming back.
This trial tests whether a personalized mRNA vaccine, given with pembrolizumab, can help people with advanced solid tumors by training the immune system to recognize cancer. It is mainly for patients whose tumor tissue matches specific genetic and immune patterns, and who meet key safety and infection requirements.
This trial tests a personalized mRNA vaccine designed to teach your immune system to attack your specific tumor. It is for people with advanced gastrointestinal cancers who have exhausted other options.
Hear when a new Pancreatic Cancer Resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.